Keymessages about Swiss Biotech in one slide (Frederik Schmachtenberg, EY, presenting) ©BIOCOM AG, gk

Swiss Biotech Report: Sunrise, not sunset, is the feeling of the hour

In 2022, the Swiss biotech industry "continued to demonstrate its resilience, adapting well to geopolitical upheavals and remaining a key driver of innovation for global healthcare". Swiss biotech companies generated revenues of CHF 6.8bn. Capital inflows amounted to more than CHF 1.3bn, of which CHF 780m went to listed companies and CHF 550m to private companies. These are some of the findings of the annual industry report published by the Swiss Biotech Association in collaboration with EY and presented at Swiss Biotech Day in Basel.

Read more
3BP's targeted radiopharmaceuticals can destroy target expressing cancer cells as well as neighboring tumour cells and cells from the microenvironment by direct radiation-induced cell damage and via the bystander and cross-fire effect. © 3B Pharmaceuticals GmbH

Novartis in US$465m deal with 3B Pharmaceuticals GmbH

Targeted radiopharmaceuticals maker 3B Pharmaceuticals snaps US$40m upfront in a global exclusive licensing agreement for its FAP-Targeting Peptide Technology.

Read more
Agrobody foundry. © Biotalys NV
partnership

Syngenta partners with Biotalys

Syngenta has announced to leverage Biotalys’ AGROBODY technology platform to expand its biocontrol pipeline.

Read more
Team of Phialogics (from left: Andreas Ernst, acting CEO, CSO; Michael J. Parnham; Andreas von Knethen; Pascal Oromi, CBO; Andreas Weigert. © Phialogics AG

Phialogics AG bags pre-seed financing

Phialogics AG has got a €600,000 pre-seed financing from German HTGF to validate its approach to rebalance the immune system of people with auto-immune diseases.

Read more
© pixabay.com/moerschy

Forbion raises €1.35bn across two funds

European life sciences venture capital company Forbion has raised two oversubscribed funds totalling €1.35 bn.

Read more
© Ariceum Therapeutics

Ariceum Therapeutics extends Series A to €47.75m

German radiopharmaceuticals developer Ariceum Therapeutics has raised a further €22.75m extension of its €25m Series A financing announced in June 2022.

Read more
agenX
Collaboration

Genmab and argenx combine antibody know-how

Genmab and argenx have entered a multiyear collaboration bringing together capabilities to jointly discover, develop and commercialise antibody therapies.

Read more
Flow cell. © Adaptyv Biosystems Sàrl

Adaptyv Biosytems launches protein engineering foundry

Swiss Adaptyv Biosystems Sàrl has launched two fast-feedback tools that allow cheap, rapid and minaturised validation of AI-designed proteins.

Read more
© NCI

Researchers activate chemotherapeutics by ultrasound

Ultrasound that switches cancer drug on could significantly reduce chemotherapy side effects, German researchers found in preclinical studies.

Read more
Thin cell-based beefsteak prototype. © Aleph Farms

FAO presents food safety assessment on cell-based protein products

At the beginning of April, the FAO presented a report entitled "Food safety aspects of cell-based food" to establish safety standards for cell-based proteins.

Read more